Boston Scientific Corporation $BSX Shares Bought by QRG Capital Management Inc.

QRG Capital Management Inc. grew its position in shares of Boston Scientific Corporation (NYSE:BSX) by 11.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 182,600 shares of the medical equipment provider’s stock after purchasing an additional 18,238 shares during the period. QRG Capital Management Inc.’s holdings in Boston Scientific were worth $19,613,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. 1248 Management LLC purchased a new stake in Boston Scientific during the 1st quarter worth $26,000. Y.D. More Investments Ltd acquired a new stake in shares of Boston Scientific during the first quarter valued at about $27,000. Sound Income Strategies LLC increased its position in shares of Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares during the last quarter. Oliver Lagore Vanvalin Investment Group acquired a new position in shares of Boston Scientific in the second quarter worth about $37,000. Finally, Activest Wealth Management lifted its stake in shares of Boston Scientific by 6,216.7% in the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock worth $38,000 after acquiring an additional 373 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on BSX. Erste Group Bank downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday. Wells Fargo & Company lifted their price target on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research note on Thursday, July 24th. Jefferies Financial Group reaffirmed a “hold” rating on shares of Boston Scientific in a report on Monday, July 21st. Finally, Oppenheimer raised shares of Boston Scientific from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $118.00 to $125.00 in a report on Monday, September 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $120.79.

Boston Scientific Stock Performance

Shares of BSX opened at $97.30 on Friday. The stock has a market capitalization of $144.17 billion, a PE ratio of 57.91, a price-to-earnings-growth ratio of 2.34 and a beta of 0.61. The business’s fifty day moving average price is $102.93 and its 200 day moving average price is $102.06. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the prior year, the company earned $0.62 earnings per share. The firm’s revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. The trade was a 42.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of the company’s stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the transaction, the director owned 2,081 shares of the company’s stock, valued at approximately $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 174,214 shares of company stock worth $17,972,457. Insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.